PPARγ agonist treatment reduces fibroadipose tissue in secondary lymphedema by exhausting fibroadipogenic PDGFRα+ mesenchymal cells.
Chen Z, Ghavimi SAA, Wu M, McNamara J, Barreiro O, Maridas D, Kratchmarov R, Siegel A, Djeddi S, Gutierrez-Arcelus M, Brennan PJ, Padera TP, von Andrian U, Mehrara B, Greene AK, Kahn CR, Orgill DP, Sinha I, Rosen V, Agarwal S.
Chen Z, et al. Among authors: ghavimi saa.
JCI Insight. 2023 Dec 22;8(24):e165324. doi: 10.1172/jci.insight.165324.
JCI Insight. 2023.
PMID: 38131378
Free PMC article.